- Home
- GHI vs IMUX Comparison
GHI vs IMUX Comparison
Compare GHI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GHI
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
Company Overview
Basic Information| Metric | GHI | IMUX |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.3M | 155.8M |
| IPO Year | 1998 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GHI | IMUX |
|---|---|---|
| Price | $5.77 | $8.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $10.50 | ★ $36.00 |
| AVG Volume (30 Days) | 32.7K | ★ 366.7K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 22.93% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,389,766.00 | N/A |
| Revenue This Year | $273.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.71 | $0.51 |
| 52 Week High | $10.46 | $17.43 |
Technical Indicators
Market Signals| Indicator | GHI | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 27.68 |
| Support Level | $5.61 | $0.78 |
| Resistance Level | $6.14 | $11.28 |
| Average True Range (ATR) | 0.15 | 0.65 |
| MACD | -0.05 | -0.11 |
| Stochastic Oscillator | 4.76 | 7.96 |
Price Performance
Historical ComparisonAbout GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.